

Synthesis of symmetrically substituted 1,4- bis [(aminoalkyl) amino]-5,8-Dimethylantracene-9,10-diones

David E. Horn*, Michael S. Leonard, Amy J. Fischl, Maribel Gray, David W. Clark, Tim Averion-Mahlock, and Camil N. Sader

Department of Chemistry, Goucher College, Towson, Maryland 21204-2794

E-mail: dhorn@goucher.edu

(received 15 Sep 00; accepted 26 Nov 00; published on the web 04 Dec 00)


Abstract

A three-step synthesis was used to prepare several symmetrically substituted 1,4-bis [(aminoalkyl) amino]-5,8-dimethylantracene-9, 10-diones commencing from 3,6-difluorophthalic anhydride.

Keywords: 5,8-Dimethylantracene-9,10-diones, difluorophthalic anhydride

Introduction


Synthetic routes to anthracenediones having specific substitution patterns have been a major interest in organic chemistry for more than a decade.¹ The synthesis and antineoplastic evaluations of a number of symmetrically substituted 1,4-bis [(aminoalkyl) amino] anthracene-9, 10-diones have been reported.¹⁻⁵ In particular, ametantrone (**1**), and its 5,8-dihydroxy-substitued congener, mitoxantrone (**2**), have shown outstanding antineoplastic activity.²⁻⁵ Although **2** is widely used clinically in the management of leukemias and lymphomas, it suffers from the toxic side effects of myelosuppression and cardiotoxicity.



- 1**, R = (CH₂)₂NH(CH₂)₂OH, X = H
2, R = (CH₂)₂NH(CH₂)₂OH, X = OH

The cell killing effects of **2** are probably multimodal in nature.^{6,7} It has been suggested that intercalation⁸ into DNA is a major cellular event and that this intercalative interaction may serve for the disruption of DNA-protein interactions, specifically the interference with topoisomerase II.^{9,10} Consequently, these drugs may be considered as having a DNA intercalation domain (the anthracene-9,10-dione region) with the protonated distal amino side-arms forming hydrogen bonds between the polar phosphate groups of the DNA backbone which stabilize the DNA-drug complex. Mitoxantrone **2** has a higher DNA binding constant and a 10-fold greater therapeutic efficacy in comparison with ametantrone (**3**). On the other hand the evaluation of molecules with non-polar substituents in the carbocyclic A-ring to assess the importance of DNA binding, in particular intercalation, have not been reported.


The goal of this research was the synthesis and antitumor evaluations of molecules related to **2** but with lipophilic (non-polar groups such as methyl groups) constituents as C-1 and C-4. The DNA interaction (binding constants) and antitumor activities of these molecules would be determined and contrasted to exhibited by mitoxantrone **2** and related chemotypes. This data could lead to a better understanding of the electronic and steric requirements for substrates in the intercalative action with DNA. Our efforts were directed toward the synthesis of analogue **3** in which the 5,8-hydroxyl groups of mitoxantrone **2** have been replaced by methyl groups. Congeners **4** and **5**, bearing the same methyl substitution pattern would also be prepared and biologically evaluated to assess the influence of the distal side arms on DNA binding and antitumor activity.



- 3**, R = NH(CH₂)₂NH(CH₂)₂OH
- 4**, R = NH(CH₂)₂N(CH₃)₂
- 5**, R = NH(CH₂)₂NH₂


The synthetic pathway leading to the difluoro analogue **9** (the precursor to **3**, **4** and **5**) is illustrated in Scheme 1. Difluoro analogue **9** appeared to be the ideal intermediate for the preparation of chemotypes **3**, **4**, and **5** based on the relatively facile S_NAr displacements by amines of fluorides in related difluoranthracenediones¹¹ and azaanthracenediones.¹²

The keto acid **8** (71%) was readily obtained via a Friedel-Crafts acylation of p-xylene (**6**) with 3,6-difluorophthalic anhydride (**7**).¹³ Subsequent ring closure of the keto acid **8** with polyphosphoric acid led to **9**. It might be noted that the aryne route¹⁴ leading to anthracene-9,10-diones might be adaptable for the synthesis of **9**.



Scheme 1

Treatment of **9** with 2-(2-aminoethylamino) ethanol (3 molar equivalent excess) in DMSO at room temperature for 72 h afforded the disubstituted product **3** (Scheme 2) which was purified by recrystallization. Although displacements of the fluorides were rapid, the long reaction time led to complete conversion to the product. Analogues **4** and **5** were obtained in a similar manner by treatment of **9** with the appropriate amines and were purified by crystallization and chromatography, respectively.



Scheme 2

The biological activities for the synthetics **3**, **4** and **5** (and their corresponding hydrochloride or dimaleate salts) will be reported elsewhere.

Experimental Section

General Procedures. Melting points were determined on a Thomas-Hoover melting point apparatus and are uncorrected. The ^1H NMR spectra were recorded on a Bruker 400 MHz DRX pulsed Fourier transform NMR spectrometer. Precoated TLC silica gel plates (Whatman) were used to monitor reactions. Sigma 100-200 mesh silica gel was utilized for column chromatography. Microanalyses were performed by Quantitative Technologies, Inc., Whitehouse NJ.

(3,6-Difluorophthaloyl)-2,5-dimethylbenzene (8). Aluminum chloride (2.0 g, 15 mol) was combined with 3,6-difluorophthalic anhydride (0.5 g, 2.7 mmol) and *p*-xylene (10 mL, 81.6 mmol) in a 50 mL round bottom flask, which was fitted with a reflux condenser. The red-orange solution was refluxed at 135-140 °C for 1 h. The black solution was cooled in an ice bath for 1h. Upon the addition of cold water (10 mL), the solution turned from black to afford a yellow suspension. Concentrated HCl (2 mL) was added to bring the pH to 1. Ether (5 mL) and cold water (5 mL) were added, and the organic layer was separated and washed with cold water. The keto acid was extracted from the organic layer with 10% NaOH (2 mL). The aqueous layer was separated, and the organic layer was extracted with further 1 mL portions of 10% NaOH. The aqueous extracts were combined, acidified to pH 1-2, cooled in an ice bath and the keto acid was collected by filtration (560 mg, 71%); mp 151-2 °C: ¹H NMR (DMSO-*d*₆) δ 10.1 (s, 1H), 7.65 (m, 2H), 7.28 (q, 2H), 7.16 (s, 1H), 2.46 (s, 3H), 2.22 (s, 3H).

Anal. Calcd for C₁₆H₁₂F₂O₃: C, 66.20; H, 4.17. Found: C, 66.34; H, 4.28.

1,4-Difluoro-5,8-dimethylanthracene-9,10-dione (9). Polyphosphoric acid (8.75 g, 89.2 mmol) was added to (3,6-difluorophthaloyl)-2,5-dimethyl benzene (**8**, 560 mg, 1.9 mmol) and the mixture was stirred and maintained at 190 °C for 1 h. The resulting black tar was cooled to 0°C. Ice water (25 mL) was added, the black solid was collected by filtration and dried. The black solid was triturated with chloroform and the solid collected by filtration. The filtrate was treated with decolorizing carbon, dried with MgSO₄, filtered to remove the charcoal and concentrated under vacuum. The crude material was purified by column chromatography using alumina as the stationary phase and chloroform as the eluent to afford a yellow product (467 mg, 89%); mp 260-262 °C: ¹H NMR (CDCl₃) δ 7.3- 7.5 (m, 4H), 2.72 (s, 6H).

Anal. Calcd for C₁₆H₁₀F₂O₂: C, 70.59; H, 3.71. Found: C, 70.32; H, 4.05.

1,4-Bis[[2-hydroxyethyl)amino]ethyl]amino-5,8-dimethylanthracene-9,10-dione (3). The 2-(2-aminoethylamino)ethanol (150 mg, 1.4 mmol) was added to 1,4-difluoro-5,8-dimethylanthracene-9,10-dione (**9**, 100 mg, 0.4 mmol) which was dissolved in DMSO (2 mL). The reaction mixture was stirred at room temperature for 72h and quenched by pouring into ice water (5 mL). The mixture was extracted with chloroform and the chloroform removed under vacuum to afford the crude material. This material was recrystallized from hexane:chloroform to yield **3** as a blue solid (52 mg, 32%); mp 155-157 °C: ¹H NMR (CDCl₃) δ 10.25 (t, 2H), 7.30 (s, 2H), 7.15 (s, 2H), 3.7 (t, 4H), 3.45 (q, 4H) 3.0 (t, 4H), 2.9 (t, 4H), 2.8 (s, 6H).

Anal. Calcd for C₂₄H₃₂N₄O₄: C, 65.43; H, 7.32; N, 12.72. Found: C, 64.99; H, 6.99; N, 12.64.

1,4-Bis[[2-(dimethylamino)ethyl]amino]-5,8-dimethylanthracene-9,10-dione (4). The 2-(dimethylamino)ethylamine (150 mg, 1.7 mmol) was added to 1,4-difluoro-5,8-dimethylanthracene-9,10-dione (**9**, 80 mg, 0.3 mmol) dissolved in DMSO (2 mL). The reaction was allowed to proceed at room temperature with stirring for 96 h. The reaction mixture was then poured onto ice water (25 mL) and the solid collected by filtration. The crude solid (102 mg, 85%) which was dissolved in chloroform:methanol was added to a silica gel column and the

impurities were eluted with chloroform and methanol. The blue product **4**, which adhered to the gel, was removed by boiling the gel with hot methanol:chloroform (2:1). Removal of the solvents led to **4**; mp 153-155°C: ¹H NMR (CDCl₃) δ 9.95 (t, 2H), 7.30 (s, 2H), 7.15 (s, 2H), 3.45 (m, 4H), 2.85 (s, 6H), 2.65 (t, 4H), 2.35 (s, 12H).

Anal Calcd for C₂₄H₃₂N₄O₂: C, 70.56; H, 7.89. Found: C, 70.31; H, 7.90.

1,4-Bis[(2-aminoethyl)amino]-5,8-dimethylantracene-9,10-dione (5). A mixture of 1,4-difluoro-5,8-dimethylantracene-9,10-dione (**9**, 100 mg, 0.4 mmol) and 1,2-diaminoethane (600 mg, 10 mmol) in DMSO (10 mL) was stirred at room temperature for 72 h. Ice cold brine (4 mL) was added, and the blue solid was collected by filtration, washed with cold water and dried (120 mg, 94%). Recrystallization was accomplished from chloroform/hexane to give a blue solid; mp 208-210 °C: ¹H NMR (CDCl₃) δ 10.09 (br s, 2H), 7.35 (s, 2H), 7.15 (s, 2H), 3.35 (m, 4H), 3.05 (t, 4H), 2.85 (s, 6H).

Anal. Calcd for C₂₀H₂₄N₄O₂: C, 68.16; H, 6.86. Found: C, 67.96; H, 6.67.

Acknowledgement

This project was supported by a grant from the Goucher College Faculty Summer Research Fund.

References and Notes

1. Krapcho, A. P.; Maresch, M. J.; Hacker, M. P.; Hazelhurst, L.; Menta, E.; Oliva, A.; Spinelli, S.; Beggiolin, G.; Giuliani, F. C.; Pezzoni, G.; Tognella, S. *Curr. Med. Chem.* **1995**, *2*, 803.
2. Zee-Cheng, R. K. Y.; Cheng, C. C. *J. Med. Chem.* **1978**, *21*, 291.
3. Cheng, C. C.; Zee-Cheng, R. K. Y. In *Prog. Med. Chem.*; Ellis, G. P.; West, G. B., Eds.; Elsevier, Amsterdam, **1983**, p 84 and references cited therein.
4. Zee-Cheng, R. K. Y.; Cheng, C. C. *Drugs Future* **1983**, *8*, 229.
5. Murdock, K. C.; Child, R. G.; Fabio, P. F.; Angier, R. B.; Wallace, R. E.; Durr, F. E.; Citarella, R. V. *J. Med. Chem.* **1979**, *22*, 1024.
6. Krapcho, A. P.; Menta, E.; Oliva, A.; Di Domenico, R.; Fiocchi, L.; Maresch, M. J.; Gallagher, C. E.; Hacker, M. P.; Beggiolin, G.; Giuliani, F. C.; Pezzoni, G.; Spinelli, S. *J. Med. Chem.* **1998**, *41*, 5429.
7. Krapcho, A. P.; Petry, M. E.; Getahun, Z.; Landi, J. J. Jr.; Stallman, J.; Polsenberg, J. F.; Gallagher, C. E.; Maresch, M. J.; Hacker, M. P.; Giuliani, F. C.; Beggiolin, G.; Pezzoni, G.; Menta, E.; Manzotti, C.; Oliva, A.; Spinelli, S.; Tognella, S. *J. Med. Chem.* **1994**, *37*, 828.

8. Pindur, U.; Haber, M.; Sattler, K. *J. Chem. Educ.* **1993**, *70*, 263.
9. Hande, K. R. *Biochim. Biophys. Acta.* **1998**, *1400*, 173.
10. Gatto, B.; Capranico, G.; Palumbo, M. *Curr. Pharm. Des.* **1999**, *5*, 195.
11. Krapcho, A. P.; Getahun, Z.; Avery, K.J. Jr. *Syn. Commun.* **1990**, 2139
12. Krapcho, A. P.; Ellis, M. *J. Fluorine Chem.* **1998**, *90*, 139.
13. Purchased from Aldrich Chemical Co.
14. Khanapure, S. P.; Biehl, E. R. *J. Nat. Prod.* **1989**, *52*, 1357.